{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:47:39Z","timestamp":1790981259025,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.gofs.2021.03.025","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T20:52:23Z","timestamp":1616273543000},"page":"394-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Syndrome g\u00e9nito-urinaire de la m\u00e9nopause (SGUM). RPC les femmes m\u00e9nopaus\u00e9es du CNGOF et du GEMVi"],"prefix":"10.1016","volume":"49","author":[{"given":"C.","family":"Hock\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grellety-Cherbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0635","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2015.07.020","article-title":"Update on management of genitourinary syndrome of menopause: a practical guide","volume":"82","author":"Palacios","year":"2015","journal-title":"Maturitas"},{"issue":"12","key":"10.1016\/j.gofs.2021.03.025_bib0640","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.mayocp.2017.08.019","article-title":"Genitourinary syndrome of menopause: management strategies for the clinician","volume":"92","author":"Faubion","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.gofs.2021.03.025_bib0645","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause N Y N"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0650","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/13697137.2015.1107039","article-title":"Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey","volume":"19","author":"Nappi","year":"2016","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"11","key":"10.1016\/j.gofs.2021.03.025_bib0655","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.purol.2012.08.267","article-title":"[Urinary incontinence and menopause]","volume":"22","author":"Legendre","year":"2012","journal-title":"Prog Urol"},{"issue":"11","key":"10.1016\/j.gofs.2021.03.025_bib0660","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00192-019-03991-0","article-title":"The experience of genitourinary syndrome of menopause (GSM) among Thai postmenopausal women: the non-reporting issue","volume":"30","author":"Srisukho","year":"2019","journal-title":"Int Urogynecol J"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0665","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13697137.2018.1529748","article-title":"Vaginal atrophy across the menopausal age: results from the ANGEL study","volume":"22","author":"Cagnacci","year":"2019","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib0670","first-page":"168","article-title":"Genitourinary syndrome of menopause\u00a0\u2013\u00a0is the problem solved? State of the art 2018","volume":"17","author":"Szyma\u0144ski","year":"2018","journal-title":"Przeglad Menopauzalny Menopause Rev"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib0675","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.maturitas.2004.06.019","article-title":"Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative","volume":"49","author":"Pastore","year":"2004","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0680","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal Health: Insights, Views & Attitudes (VIVA)\u00a0\u2013\u00a0results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0685","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/13697137.2017.1421921","article-title":"Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study","volume":"21","author":"Moral","year":"2018","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0690","first-page":"351","article-title":"A prospective population-based study of menopausal symptoms","volume":"96","author":"Dennerstein","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"Suppl. 12B","key":"10.1016\/j.gofs.2021.03.025_bib0695","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2005.09.031","article-title":"Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives","volume":"118","author":"Woods","year":"2005","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0700","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.maturitas.2010.08.001","article-title":"Women's voices in the menopause: results from an international survey on vaginal atrophy","volume":"67","author":"Nappi","year":"2010","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib0705","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/13697137.2018.1482647","article-title":"Sexual well-being after menopause: an International Menopause Society White Paper","volume":"21","author":"Simon","year":"2018","journal-title":"Climacteric J Int Menopause Soc"},{"key":"10.1016\/j.gofs.2021.03.025_bib0710","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.maturitas.2016.09.013","article-title":"Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL)","volume":"94","author":"Nappi","year":"2016","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib0715","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.maturitas.2015.05.007","article-title":"Characteristics of postmenopausal women with genitourinary syndrome of menopause: implications for vulvovaginal atrophy diagnosis and treatment selection","volume":"81","author":"Castelo-Branco","year":"2015","journal-title":"Maturitas"},{"issue":"Suppl. 1","key":"10.1016\/j.gofs.2021.03.025_bib0720","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.maturitas.2005.06.014","article-title":"Management of postmenopausal vaginal atrophy and atrophic vaginitis","volume":"52","author":"Castelo-Branco","year":"2005","journal-title":"Maturitas"},{"key":"10.1016\/j.gofs.2021.03.025_bib0725","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.maturitas.2017.03.315","article-title":"Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning","volume":"100","author":"Pinkerton","year":"2017","journal-title":"Maturitas"},{"issue":"10","key":"10.1016\/j.gofs.2021.03.025_bib0730","first-page":"3090","article-title":"Diagnosis and treatment of atrophic vaginitis","volume":"61","author":"Bachmann","year":"2000","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0735","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5114\/pm.2019.84152","article-title":"Genitourinary syndrome of menopause: effects on related factors, quality of life, and self-care power","volume":"18","author":"Karako\u00e7","year":"2019","journal-title":"Przeglad Menopauzalny Menopause Rev"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0740","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0745","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/13697137.2015.1124259","article-title":"Treating vulvovaginal atrophy\/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?","volume":"19","author":"Edwards","year":"2016","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"11","key":"10.1016\/j.gofs.2021.03.025_bib0750","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0755","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-5122(95)00955-8","article-title":"Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women","volume":"23","author":"Bygdeman","year":"1996","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0760","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2015.07.020","article-title":"Update on management of genitourinary syndrome of menopause: a practical guide","volume":"82","author":"Palacios","year":"2015","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib0765","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/jsm.12125","article-title":"Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial","volume":"10","author":"Chen","year":"2013","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0770","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00404-010-1382-8","article-title":"The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial","volume":"283","author":"Ekin","year":"2011","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0775","first-page":"69","article-title":"Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial","volume":"4","author":"Jokar","year":"2016","journal-title":"Int J Community Based Nurs Midwifery"},{"issue":"8","key":"10.1016\/j.gofs.2021.03.025_bib0780","first-page":"CD001500","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gofs.2021.03.025_bib0785","first-page":"CD001405","article-title":"Oestrogen therapy for urinary incontinence in postmenopausal women","volume":"10","author":"Cody","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0790","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/GME.0000000000000485","article-title":"Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel","volume":"23","author":"Caruso","year":"2016","journal-title":"Menopause N Y N"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0795","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/jwh.2017.6515","article-title":"A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom","volume":"27","author":"Archer","year":"2018","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0800","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/GME.0000000000000985","article-title":"A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom","volume":"25","author":"Kroll","year":"2018","journal-title":"Menopause N Y N"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0805","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/13697137.2017.1421923","article-title":"Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review","volume":"21","author":"Mueck","year":"2018","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0810","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/13697137.2013.769097","article-title":"Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy","volume":"16","author":"Jaisamrarn","year":"2013","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0815","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00404-013-3030-6","article-title":"Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women","volume":"289","author":"Capobianco","year":"2014","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0820","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0825","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2010.483297","article-title":"Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets","volume":"13","author":"Eugster-Hausmann","year":"2010","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0830","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/gme.0b013e31817b6132","article-title":"Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause N Y N"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib0835","first-page":"556","article-title":"Estradiol absorption from vaginal tablets in postmenopausal women","volume":"99","author":"Notelovitz","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0840","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0378-5122(89)90120-5","article-title":"Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy","volume":"11","author":"Holmgren","year":"1989","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib0845","first-page":"2757","article-title":"Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women","volume":"86","author":"Naessen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib0850","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1067\/mob.2002.122143","article-title":"Endometrial thickness and uterine diameter not affected by ultralow doses of 17\u03b2-estradiol in elderly women","volume":"186","author":"Naessen","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.gofs.2021.03.025_bib0855","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause N Y N"},{"issue":"7","key":"10.1016\/j.gofs.2021.03.025_bib0860","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of The North American Menopause Society","volume":"24","author":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel","year":"2017","journal-title":"Menopause N Y N"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib0865","first-page":"CD001500","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","author":"Suckling","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gofs.2021.03.025_bib0870","unstructured":"Overview. Menopause: diagnosis and management. Guidance. NICE. [Internet. Cit\u00e9 9 juill 2019. Disponible sur\u00a0: https:\/\/www.nice.org.uk\/guidance\/ng23]."},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0875","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG Practice Bulletin No.\u00a0141: management of menopausal symptoms","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0880","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2012.06.009","article-title":"EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy","volume":"73","author":"Rees","year":"2012","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0885","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.maturitas.2015.02.003","article-title":"EMAS position statement: the ten-point guide to the integral management of menopausal health","volume":"81","author":"Neves-e-Castro","year":"2015","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib0890","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/gme.0b013e31819e8e2d","article-title":"Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause N Y N"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0895","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000000571","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"23","author":"Labrie","year":"2016","journal-title":"Menopause N Y N"},{"issue":"9","key":"10.1016\/j.gofs.2021.03.025_bib0900","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/GME.0000000000000428","article-title":"Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)","volume":"22","author":"Archer","year":"2015","journal-title":"Menopause N Y N"},{"issue":"12","key":"10.1016\/j.gofs.2021.03.025_bib0905","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/jsm.13045","article-title":"Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy","volume":"12","author":"Labrie","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.gofs.2021.03.025_bib0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2017.03.014","article-title":"Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 \u03bcg estradiol on symptoms of vulvovaginal atrophy","volume":"174","author":"Archer","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib0915","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.maturitas.2015.02.005","article-title":"Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study","volume":"81","author":"Labrie","year":"2015","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib0920","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/gme.0b013e31819e8930","article-title":"Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause N Y N"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0925","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1515\/hmbci-2015-0035","article-title":"Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA","volume":"24","author":"Ke","year":"2015","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"12","key":"10.1016\/j.gofs.2021.03.025_bib0930","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/GME.0000000000000470","article-title":"Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women","volume":"22","author":"Portman","year":"2015","journal-title":"Menopause N Y N"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib0935","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/jsm.12473","article-title":"Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial","volume":"11","author":"Fernandes","year":"2014","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0940","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1743-6109.2009.01667.x","article-title":"A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women","volume":"7","author":"Raghunandan","year":"2010","journal-title":"J Sex Med"},{"issue":"4, Part 2","key":"10.1016\/j.gofs.2021.03.025_bib0945","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0029-7844(98)00175-6","article-title":"Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee","volume":"92","author":"Cardozo","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"5 Pt 1","key":"10.1016\/j.gofs.2021.03.025_bib0950","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/01.AOG.0000158120.47542.18","article-title":"Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative","volume":"105","author":"Barnabei","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib0955","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0029-7844(96)00281-5","article-title":"Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group","volume":"88","author":"Fantl","year":"1996","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0960","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00192-003-1054-3","article-title":"A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women","volume":"14","author":"Rufford","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"5 Pt 1","key":"10.1016\/j.gofs.2021.03.025_bib0965","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/01.AOG.0000180394.08406.15","article-title":"Postmenopausal hormone therapy: does it cause incontinence?","volume":"106","author":"Steinauer","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.gofs.2021.03.025_bib0970","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.293.8.935","article-title":"Effects of estrogen with and without progestin on urinary incontinence","volume":"293","author":"Hendrix","year":"2005","journal-title":"JAMA"},{"issue":"5 Pt 1","key":"10.1016\/j.gofs.2021.03.025_bib0975","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/01.AOG.0000182576.48290.6d","article-title":"The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women","volume":"106","author":"Waetjen","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.gofs.2021.03.025_bib0980","first-page":"CD008536","article-title":"Short-term and long-term effects of tibolone in postmenopausal women","volume":"10","author":"Formoso","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib0985","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause N Y N"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib0990","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause N Y N"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib0995","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib1000","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/GME.0000000000001292","article-title":"Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial","volume":"26","author":"Archer","year":"2019","journal-title":"Menopause N Y N"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","article-title":"Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial","volume":"18","author":"Constantine","year":"2015","journal-title":"Climacteric"},{"issue":"8","key":"10.1016\/j.gofs.2021.03.025_bib1010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/09513590.2018.1441398","article-title":"Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?","volume":"34","author":"Schiavi","year":"2018","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09513590.2018.1500534","article-title":"Usefulness of Ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery","volume":"35","author":"Schiavi","year":"2019","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/09513590.2017.1370645","article-title":"Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene","volume":"34","author":"Schiavi","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.gofs.2021.03.025_bib1025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.maturitas.2018.11.016","article-title":"Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy","volume":"121","author":"Di Donato","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.gofs.2021.03.025_bib1030","first-page":"CD011066","article-title":"Dehydroepiandrosterone for women in the peri- or postmenopausal phase","volume":"1","author":"Scheffers","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib1035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13697137.2019.1637079","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"22","author":"Davis","year":"2019","journal-title":"Climacteric"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib1040","first-page":"CD004509","article-title":"Testosterone for peri- and postmenopausal women","author":"Somboonporn","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib1045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2053369118823365","article-title":"An overview of the phytoestrogen effect on vaginal health and dyspareunia in peri- and postmenopausal women","volume":"25","author":"Dizavandi","year":"2019","journal-title":"Post Reprod Health"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13697139909025570","article-title":"The effect of Promensil\u2122, an isoflavone extract, on menopausal symptoms","volume":"2","author":"Knight","year":"1999","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib1055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/13697130008500108","article-title":"The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women","volume":"3","author":"Kotsopoulos","year":"2000","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib1060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09513590500361192","article-title":"The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study","volume":"21","author":"Hidalgo","year":"2005","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib1065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.maturitas.2005.02.009","article-title":"Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study","volume":"53","author":"Kaari","year":"2006","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib1070","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/gme.0b013e3180399486","article-title":"Effect of Pueraria mirifica on vaginal health","volume":"14","author":"Manonai","year":"2007","journal-title":"Menopause N Y N"},{"key":"10.1016\/j.gofs.2021.03.025_bib1075","first-page":"33","article-title":"The effect of soymilk on menopausal symptoms and total antioxidant levels in menopausal women","volume":"4","author":"Hanachi","year":"2008","journal-title":"Malays J Med Health Sci"},{"issue":"11","key":"10.1016\/j.gofs.2021.03.025_bib1080","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/ptr.5680","article-title":"A novel extract of Fenugreek Husk (FenuSMARTTM) alleviates postmenopausal symptoms and helps to establish the hormonal balance: a randomized, double-blind, placebo-controlled study","volume":"30","author":"Begum","year":"2016","journal-title":"Phytother Res"},{"key":"10.1016\/j.gofs.2021.03.025_bib1085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/13697139809085527","article-title":"Effects of dietary phytoestrogens in postmenopausal women","volume":"1","author":"Dalais","year":"1998","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"9","key":"10.1016\/j.gofs.2021.03.025_bib1090","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1089\/jmf.2011.0228","article-title":"Evaluation of the efficacy of flaxseed meal and flaxseed extract in reducing menopausal symptoms","volume":"15","author":"Colli","year":"2012","journal-title":"J Med Food"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GME.0000000000000742","article-title":"Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women","volume":"24","author":"Suwanvesh","year":"2017","journal-title":"Menopause N Y N"},{"key":"10.1016\/j.gofs.2021.03.025_bib1100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.maturitas.2015.11.005","article-title":"Effect of Foeniculum vulgare (fennel) vaginal cream on vaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled trial","volume":"84","author":"Yaralizadeh","year":"2016","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib1105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2053369117733629","article-title":"Effect of Foeniculum vulgare (fennel) on vaginal atrophy in postmenopausal women: a double-blind, randomized, placebo-controlled trial","volume":"23","author":"Ghazanfarpour","year":"2017","journal-title":"Post Reprod Health"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib1110","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/01.AOG.0000241091.86268.6e","article-title":"Breast cancer risk in postmenopausal women using estrogen-only therapy","volume":"108","author":"Lyytinen","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib1115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause N Y N"},{"key":"10.1016\/j.gofs.2021.03.025_bib1120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.breast.2018.07.003","article-title":"Survivorship issues as determinants of quality of life after breast cancer treatment: report from a limited resource setting","volume":"41","author":"Kaur","year":"2018","journal-title":"Breast Edinb Scotl"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-016-3827-7","article-title":"Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy","volume":"157","author":"Sulaica","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib1130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/09513590.2017.1290076","article-title":"Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?","volume":"33","author":"Oyarz\u00fan","year":"2017","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib1135","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health","volume":"25","author":"Faubion","year":"2018","journal-title":"Menopause N Y N"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib1140","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.1997.15.3.969","article-title":"Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer","volume":"15","author":"Loprinzi","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib1145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13697137.2016.1258396","article-title":"Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?","volume":"20","author":"Juliato","year":"2017","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib1150","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/AOG.0b013e3182118790","article-title":"Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial","volume":"117","author":"Lee","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib1155","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11764-017-0606-3","article-title":"A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy","volume":"11","author":"Advani","year":"2017","journal-title":"J Cancer Surviv Res Pract"},{"issue":"30","key":"10.1016\/j.gofs.2021.03.025_bib1160","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"Goetsch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib1165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clbc.2015.06.005","article-title":"Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes?","volume":"15","author":"Biglia","year":"2015","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib1170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1175","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1180","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.gofs.2021.03.025_bib1185","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors","volume":"103","author":"Davis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9407","key":"10.1016\/j.gofs.2021.03.025_bib1190","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u00a0\u2013\u00a0is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib1195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10-year follow-up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib1200","first-page":"322","article-title":"Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients?","volume":"6","author":"Lupo","year":"2015","journal-title":"J Adv Pract Oncol"},{"issue":"7","key":"10.1016\/j.gofs.2021.03.025_bib1205","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.gofs.2021.03.025_bib1210","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O\u2019Meara","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.gofs.2021.03.025_bib1215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause N Y N"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib1220","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2021.03.025_bib1225","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib1230","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J Oncol Pract"},{"issue":"2","key":"10.1016\/j.gofs.2021.03.025_bib1235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-014-2930-x","article-title":"Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor\u00ae) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study","volume":"145","author":"Donders","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib1240","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/13697137.2010.529967","article-title":"Vaginal estriol to overcome side effects of aromatase inhibitors in breast cancer patients","volume":"14","author":"Pfeiler","year":"2011","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"3","key":"10.1016\/j.gofs.2021.03.025_bib1245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs. estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2021.03.025_bib1250","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.gofs.2021.03.025_bib1255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/sm2.22","article-title":"Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy","volume":"2","author":"Dahir","year":"2014","journal-title":"Sex Med"},{"issue":"11","key":"10.1016\/j.gofs.2021.03.025_bib0630","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors","volume":"103","author":"Davis","year":"2018","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718921000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718921000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:40:09Z","timestamp":1762854009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718921000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":126,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2468718921000775"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2021.03.025","relation":{},"ISSN":["2468-7189"],"issn-type":[{"value":"2468-7189","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndrome g\u00e9nito-urinaire de la m\u00e9nopause (SGUM). RPC les femmes m\u00e9nopaus\u00e9es du CNGOF et du GEMVi","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2021.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}